D. E. Shaw & Co., Inc. Biomarin Pharmaceutical Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $28,748 - $52,412	-400 Reduced 1.96%	20,000 $1.52 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $31,820 - $49,688	400 Added 2.0%	20,400 $2.52 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $803,500 - $939,000	10,000 Added 100.0%	20,000 $1.71 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $2.95 Million - $3.52 Million	-38,000 Reduced 79.17%	10,000 $811,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $3.87 Million - $4.56 Million	48,000	48,000 $4.47 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.